LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK.
Location: Switzerland, Zurich, Schlieren
Employees: 11-50
Total raised: $46M
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | Tenmile | tenmile.co... |
| 08.11.2023 | Adjuvant C... | adjuvantca... |
| 01.03.2025 | CARB-X | carb-x.org |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.02.2025 | - | $6.5M | - |
| 01.02.2024 | Series A | $3M | - |
| 08.10.2023 | Series A | $36.5M | - |
Mentions in press and media 23
| Date | Title | Description |
| 27.05.2025 | Big Pharma-backed GlycoEra counting days to clinic with $130M raise for protein degraders | It’s GlycoEra’s time to shine. The Swiss biotech has closed a series B fundraise clocking in at $130 million, with the funds set to support clinical trials for the company’s lead autoimmune protein degrader later this year. The oversubscrib... |
| 23.04.2025 | A New Dawn in Cancer Treatment: Onward Therapeutics' Bold Move with NK Cell Therapy | In the world of biotechnology, breakthroughs often feel like whispers in a storm. Yet, some announcements resonate like thunder. Onward Therapeutics has just made such a declaration. The company, rooted in Switzerland, is stepping into the ... |
| 23.04.2025 | Swiss biotechs on track to address key medical challenges | Onward Therapeutics SA is focused on advancing innovative cancer immunotherapies through a fast-track development model. Its portfolio includes a bispecific antibody (OT-A201) licensed from Biomunex, alongside an equity investment; and an ... |
| 17.02.2025 | LimmaTech secures US$6.5 million to advance vaccine against S. aureus | LBT-SA7 is designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen Staphylococcus aureus (S. aureus). S. aureus infections pose a significant global health challenge, causing an estimated 1 million deat... |
| 08.08.2024 | New Frontiers in Vaccine Development and Cancer Treatment: A Dual Breakthrough | In the realm of healthcare, two recent developments shine like beacons of hope. LimmaTech Biologics is making strides in vaccine development, while GSK is redefining cancer treatment. Both stories reveal the relentless pursuit of innovation... |
| 08.08.2024 | The Battle Against Dementia: A New Dawn in Prevention and Awareness | Dementia looms like a shadow over millions. It’s a thief, stealing memories and identities. But recent studies shine a light on prevention. Almost half of dementia cases could be avoided. This revelation is a beacon of hope for families and... |
| 02.08.2024 | LimmaTech to receive €10 million in exclusive licensing agreement | LimmaTech Biologics is a clinical-stage startup developing vaccines for the prevention of life-threatening diseases such as Shigellosis which is caused by Shigella bacteria. Shigellosis is the second leading cause of fatal diarrheal diseas... |
| 02.08.2024 | Seasoned chairpersons and board members back life sciences startups | Anaveon, a clinical-stage company specializing in developing treatments for diseases with immune system dysfunction, focusing on biologics that modulate cytokine functions to provide therapeutic benefit has appointed former Chair and CEO o... |
| 01.03.2024 | A wave of success for LimmaTech | LimmaTech is a clinical stage biotech company that has built a robust pipeline of innovative vaccines using their proprietary self-adjuvanting and multi-antigen vaccine technology platform. The startup was awarded $2.2 million from the Com... |
| 02.02.2024 | New investment brings LimmaTech’s series A to CHF 40 million | Emerging antimicrobial resistance worldwide presents a serious public health threat. Inappropriate or excessive use of antibiotics has resulted in a major increase in bacterial resistance against the formerly effective drugs. LimmaTech aim... |
Show more